27.09.2018 • NewsElaine BurridgeIneoskoch

Ineos Takes Intermediates from Flint Hills

Ineos Takes Intermediates from Flint Hills (c) Ineos
Ineos Takes Intermediates from Flint Hills (c) Ineos

Ineos Enterprises has entered  into a binding agreement to buy the chemical intermediates business of Flint Hills Resources, a wholly owned subsidiary of Koch Industries, said to be one of the largest privately owned companies in the US. Financial terms were not disclosed.

The business comprises facilities located near Chicago, Illinois, for producing isophthalic acid (PIA), trimellitic anhydride (TMA) and maleic anhydride (MAN).  The intermediates made at the site are distributed worldwide and used in a diverse range of end-use applications such as coatings, clothing, paints and gasoline additives.

Flint Hills also has offices and distribution operations at various locations in the US, Europe and Asia. Its workforce of around 260 people will transfer to Ineos Enterprises following completion of the deal, which is expected by the end of 2018, subject to regulatory approval.

Ashley Reed, CEO of Ineos Enterprises, said the chemicals intermediates business fits well with Ineos’s portfolio, adding that the UK-based group has a track record of acquiring businesses that are no longer core to their previous owners.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.